Krebs Biochemicals & Industries Limited (KREBSBIO.BO)
INR 72.4
(1.7%)
INR 72.4
(1.7%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -197.28 Million INR | 20.1% |
| 2022 | -246.91 Million INR | 44.55% |
| 2021 | -445.26 Million INR | -57.01% |
| 2020 | -283.58 Million INR | 1.78% |
| 2019 | -288.71 Million INR | -44.28% |
| 2018 | -200.11 Million INR | -12.27% |
| 2017 | -178.24 Million INR | -11.06% |
| 2016 | -160.49 Million INR | 1.66% |
| 2015 | -163.2 Million INR | 0.0% |
| 2014 | - INR | 0.0% |
| 2011 | -174.38 Million INR | -160.96% |
| 2010 | -66.82 Million INR | -17.9% |
| 2009 | -56.67 Million INR | 86.7% |
| 2008 | -426.28 Million INR | -318.35% |
| 2007 | -101.89 Million INR | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q1 | -51.71 Million INR | 11.56% |
| 2023 Q4 | -58.47 Million INR | -17.47% |
| 2023 FY | -197.28 Million INR | 20.1% |
| 2023 Q2 | -35.71 Million INR | 33.03% |
| 2023 Q1 | -53.32 Million INR | 23.15% |
| 2023 Q3 | -49.77 Million INR | -39.37% |
| 2022 Q3 | -55.54 Million INR | -36.76% |
| 2022 Q2 | -40.61 Million INR | 50.09% |
| 2022 Q1 | -81.36 Million INR | 28.08% |
| 2022 FY | -246.91 Million INR | 44.55% |
| 2022 Q4 | -69.39 Million INR | -24.94% |
| 2021 Q3 | -129.41 Million INR | -19.29% |
| 2021 Q2 | -108.48 Million INR | -15.12% |
| 2021 Q4 | -113.13 Million INR | 12.58% |
| 2021 FY | -445.26 Million INR | -57.01% |
| 2021 Q1 | -94.23 Million INR | -34.88% |
| 2020 Q3 | -82.6 Million INR | -29.26% |
| 2020 FY | -283.58 Million INR | 1.78% |
| 2020 Q4 | -69.86 Million INR | 15.42% |
| 2020 Q1 | -67.21 Million INR | -9.16% |
| 2020 Q2 | -63.9 Million INR | 4.93% |
| 2019 Q4 | -61.57 Million INR | 15.44% |
| 2019 FY | -288.71 Million INR | -44.28% |
| 2019 Q1 | -75.86 Million INR | -45.65% |
| 2019 Q2 | -78.47 Million INR | -3.43% |
| 2019 Q3 | -72.81 Million INR | 7.21% |
| 2018 Q2 | -30.74 Million INR | 41.61% |
| 2018 Q1 | -52.65 Million INR | 29.55% |
| 2018 FY | -200.11 Million INR | -12.27% |
| 2018 Q4 | -52.09 Million INR | 19.42% |
| 2018 Q3 | -64.64 Million INR | -110.28% |
| 2017 Q3 | 4.42 Million INR | 109.1% |
| 2017 Q1 | -59.33 Million INR | -62.35% |
| 2017 Q4 | -74.73 Million INR | -1789.31% |
| 2017 FY | -178.24 Million INR | -11.06% |
| 2017 Q2 | -48.6 Million INR | 18.09% |
| 2016 Q2 | -41.59 Million INR | -11.86% |
| 2016 FY | -160.49 Million INR | 1.66% |
| 2016 Q3 | -45.16 Million INR | -8.56% |
| 2016 Q1 | -37.18 Million INR | 38.13% |
| 2016 Q4 | -36.54 Million INR | 19.07% |
| 2015 Q1 | -29.51 Million INR | 0.0% |
| 2015 FY | -163.2 Million INR | 0.0% |
| 2015 Q2 | -40.76 Million INR | -38.12% |
| 2015 Q3 | -32.82 Million INR | 19.49% |
| 2015 Q4 | -60.1 Million INR | -83.13% |
| 2014 FY | - INR | 0.0% |
| 2014 Q3 | -14 Million INR | 0.0% |
| 2013 Q2 | -19.04 Million INR | 0.0% |
| 2013 Q3 | -21 Million INR | -10.33% |
| 2012 Q3 | -80.64 Million INR | -69.81% |
| 2012 Q2 | -47.49 Million INR | 0.0% |
| 2011 Q3 | -54.26 Million INR | 6.18% |
| 2011 FY | -174.38 Million INR | -160.96% |
| 2011 Q4 | -7.22 Million INR | 86.69% |
| 2011 Q2 | -57.83 Million INR | 0.0% |
| 2010 FY | -66.82 Million INR | -17.9% |
| 2009 FY | -56.67 Million INR | 86.7% |
| 2008 FY | -426.28 Million INR | -318.35% |
| 2008 Q4 | -141.15 Million INR | 0.0% |
| 2007 FY | -101.89 Million INR | 0.0% |
| 2007 Q4 | -36.29 Million INR | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 6.15 Billion INR | 103.204% |
| Aurobindo Pharma Limited | 31.72 Billion INR | 100.622% |
| Glenmark Life Sciences Limited | 4.7 Billion INR | 104.19% |
| Granules India Limited | 4.05 Billion INR | 104.867% |
| Indoco Remedies Limited | 984.6 Million INR | 120.037% |
| Achyut Healthcare Limited | 5.73 Million INR | 3541.8% |
| Ajanta Pharma Limited | 8.16 Billion INR | 102.417% |
| Alkem Laboratories Limited | 17.95 Billion INR | 101.099% |
| Alpa Laboratories Limited | 167.76 Million INR | 217.595% |
| Brooks Laboratories Limited | -195.91 Million INR | -0.697% |
| AstraZeneca Pharma India Limited | 1.61 Billion INR | 112.215% |
| Bajaj HealthCare Limited | -837.93 Million INR | 76.456% |
| Bliss GVS Pharma Limited | 754.54 Million INR | 126.146% |
| Dr. Reddy's Laboratories Limited | 55.68 Billion INR | 100.354% |
| Eris Lifesciences Limited | 3.91 Billion INR | 105.033% |
| FDC Limited | 3.05 Billion INR | 106.464% |
| Glenmark Pharmaceuticals Limited | -15.01 Billion INR | 98.686% |
| Gufic Biosciences Limited | 861.35 Million INR | 122.904% |
| Ind-Swift Laboratories Limited | 4.2 Billion INR | 104.687% |
| Ipca Laboratories Limited | 5.47 Billion INR | 103.604% |
| Jagsonpal Pharmaceuticals Limited | 224.63 Million INR | 187.826% |
| Lasa Supergenerics Limited | -217.3 Million INR | 9.214% |
| Laurus Labs Limited | 1.6 Billion INR | 112.288% |
| Lupin Limited | 19.14 Billion INR | 101.03% |
| Mankind Pharma Limited | 19.12 Billion INR | 101.031% |
| Medicamen Biotech Limited | 109.31 Million INR | 280.481% |
| Medico Remedies Limited | 82.9 Million INR | 337.952% |
| Megasoft Limited | -127.46 Million INR | -54.774% |
| NATCO Pharma Limited | 13.88 Billion INR | 101.421% |
| Piramal Pharma Limited | 178.2 Million INR | 210.709% |
| RPG Life Sciences Limited | 876.6 Million INR | 122.506% |
| Sigachi Industries Limited | 571.8 Million INR | 134.502% |
| Sun Pharmaceutical Industries Limited | 95.76 Billion INR | 100.206% |
| Suven Pharmaceuticals Limited | 3 Billion INR | 106.57% |
| Syncom Formulations (India) Limited | 253.14 Million INR | 177.934% |
| Unichem Laboratories Limited | -704.74 Million INR | 72.006% |
| Wanbury Limited | 559.56 Million INR | 135.257% |
| Windlas Biotech Limited | 581.87 Million INR | 133.905% |
| ZIM Laboratories Limited | 172.46 Million INR | 214.391% |
| Zydus Lifesciences Limited | 38.59 Billion INR | 100.511% |
| Sun Pharma Advanced Research Company Limited | -3.87 Billion INR | 94.905% |
| Divi's Laboratories Limited | 16 Billion INR | 101.233% |
| Hester Biosciences Limited | 188.89 Million INR | 204.444% |
| Procter & Gamble Health Limited | 2 Billion INR | 109.816% |
| Amrutanjan Health Care Limited | 449.72 Million INR | 143.868% |
| Bal Pharma Limited | 73.92 Million INR | 366.881% |
| Strides Pharma Science Limited | -706.14 Million INR | 72.062% |
| Venus Remedies Limited | 284.9 Million INR | 169.245% |
| Aarti Pharmalabs Limited | 2.16 Billion INR | 109.096% |
| Nectar Lifesciences Limited | 49.95 Million INR | 494.963% |
| Shilpa Medicare Limited | 318.74 Million INR | 161.895% |
| Aarti Drugs Limited | 1.71 Billion INR | 111.509% |
| IOL Chemicals and Pharmaceuticals Limited | 1.34 Billion INR | 114.676% |
| Suven Life Sciences Limited | -1.05 Billion INR | 81.225% |
| Ind-Swift Limited | 142.31 Million INR | 238.627% |
| Valiant Laboratories Limited | 3.19 Million INR | 6272.841% |
| J. B. Chemicals & Pharmaceuticals Limited | 5.52 Billion INR | 103.57% |
| Solara Active Pharma Sciences Limited | -5.67 Billion INR | 96.523% |
| Themis Medicare Limited | 435.23 Million INR | 145.328% |
| Hikal Limited | 696.02 Million INR | 128.345% |
| Torrent Pharmaceuticals Limited | 16.56 Billion INR | 101.191% |
| Sequent Scientific Limited | -358.69 Million INR | 44.999% |
| Novartis India Limited | 851.9 Million INR | 123.158% |
| Wockhardt Limited | -4.63 Billion INR | 95.739% |
| Jubilant Pharmova Limited | 771 Million INR | 125.588% |
| Biofil Chemicals and Pharmaceuticals Limited | 7.09 Million INR | 2881.782% |
| Neuland Laboratories Limited | 3 Billion INR | 106.574% |
| Morepen Laboratories Limited | 961.59 Million INR | 120.516% |
| Kilitch Drugs (India) Limited | 146.01 Million INR | 235.113% |
| Mangalam Drugs & Organics Limited | -90.71 Million INR | -117.472% |